Segment Reporting - Schedule of Revenues, Operating Expenses and Operating Income (Loss) by Reportable Segment (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2019 |
Sep. 30, 2018 |
Sep. 30, 2019 |
Sep. 30, 2018 |
|
| Net revenue | $ 16,851,328 | $ 17,044,526 | $ 48,681,038 | $ 34,034,788 |
| Direct operating costs | 10,535,629 | 12,123,907 | 31,779,564 | 20,941,535 |
| Selling and marketing | 347,568 | 461,512 | 1,091,524 | 1,169,583 |
| General and administrative | 4,451,975 | 5,131,295 | 13,757,805 | 10,786,234 |
| Research and development | 175,758 | 263,717 | 648,822 | 768,517 |
| Change in contingent consideration | (279,565) | 25,473 | (343,768) | 68,253 |
| Depreciation and amortization | 814,210 | 822,098 | 2,407,111 | 1,972,565 |
| Restructuring and impairment charges | 136,332 | 136,332 | ||
| Total operating expenses | 16,181,907 | 18,828,002 | 49,477,390 | 35,706,687 |
| Operating income (loss) | 669,421 | (1,783,476) | (796,352) | (1,671,899) |
| Healthcare IT [Member] | ||||
| Net revenue | 12,938,042 | 13,730,105 | 38,518,361 | 30,720,367 |
| Direct operating costs | 7,508,208 | 9,485,642 | 23,912,120 | 18,303,270 |
| Selling and marketing | 339,603 | 451,872 | 1,065,750 | 1,159,943 |
| General and administrative | 2,791,573 | 2,730,595 | 8,549,122 | 6,591,165 |
| Research and development | 175,758 | 263,717 | 648,822 | 768,517 |
| Change in contingent consideration | (279,565) | 25,473 | (343,768) | 68,253 |
| Depreciation and amortization | 735,133 | 740,342 | 2,170,204 | 1,890,809 |
| Restructuring and impairment charges | 136,332 | 136,332 | ||
| Total operating expenses | 11,407,042 | 13,697,641 | 36,138,582 | 28,781,957 |
| Operating income (loss) | 1,531,000 | 32,464 | 2,379,779 | 1,938,410 |
| Practice Management [Member] | ||||
| Net revenue | 3,913,286 | 3,314,421 | 10,162,677 | 3,314,421 |
| Direct operating costs | 3,027,421 | 2,638,265 | 7,867,444 | 2,638,265 |
| Selling and marketing | 7,965 | 9,640 | 25,774 | 9,640 |
| General and administrative | 548,746 | 552,514 | 1,504,506 | 552,514 |
| Research and development | ||||
| Change in contingent consideration | ||||
| Depreciation and amortization | 79,077 | 81,756 | 236,907 | 81,756 |
| Restructuring and impairment charges | ||||
| Total operating expenses | 3,663,209 | 3,282,175 | 9,634,631 | 3,282,175 |
| Operating income (loss) | 250,077 | 32,246 | 528,046 | 32,246 |
| Unallocated Corporate Expenses [Member] | ||||
| Net revenue | ||||
| Direct operating costs | ||||
| Selling and marketing | ||||
| General and administrative | 1,111,656 | 1,848,186 | 3,704,177 | 3,642,555 |
| Research and development | ||||
| Change in contingent consideration | ||||
| Depreciation and amortization | ||||
| Restructuring and impairment charges | ||||
| Total operating expenses | 1,111,656 | 1,848,186 | 3,704,177 | 3,642,555 |
| Operating income (loss) | $ (1,111,656) | $ (1,848,186) | $ (3,704,177) | $ (3,642,555) |